Is Denali Therapeutics Inc. (DNLI) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.6% / 30% | 27.1% / 30% | 0.1% / 30% | N/A | ✓ HALAL |
| DJIM | 1.6% / 33% | 27.1% / 33% | 0.1% / 33% | N/A | ✓ HALAL |
| MSCI | 3.5% / 33% | 60.6% / 33% | 0.2% / 33% | N/A | ✗ NOT HALAL |
| S&P | 1.6% / 33% | 27.1% / 33% | 0.1% / 33% | N/A | ✓ HALAL |
| FTSE | 3.5% / 33% | 60.6% / 33% | 0.2% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -45.7% | |
| Return on Assets (ROA) | -27.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$413M |
| Free Cash Flow | -$422M |
| Total Debt | $37M |
| Debt-to-Equity | 4.2 |
| Current Ratio | 9.2 |
| Total Assets | $1.1B |
Price & Trading
| Last Close | $19.73 |
| 50-Day MA | $20.43 |
| 200-Day MA | $16.81 |
| Avg Volume | 1.6M |
| Beta | 1.1 |
|
52-Week Range
$10.57
| |
About Denali Therapeutics Inc. (DNLI)
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Denali Therapeutics Inc. (DNLI) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Denali Therapeutics Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Denali Therapeutics Inc.'s debt ratio?
Denali Therapeutics Inc.'s debt ratio is 1.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 3.5%.
What are Denali Therapeutics Inc.'s key financial metrics?
Denali Therapeutics Inc. has a market capitalization of $2.9B. Return on equity stands at -45.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.